tetano
Editor, Senior Moderator
ACS Appl Polym Mater
. 2023 Feb 23;acsapm.2c02187.
doi: 10.1021/acsapm.2c02187. Online ahead of print. Method for the Rapid Detection of SARS-CoV-2-Neutralizing Antibodies Using a Nanogel-Based Surface Plasmon Resonance Biosensor
Su-Kyoung Lee[SUP] 1 2 [/SUP], Bora Yim[SUP] 1 2 [/SUP], Jinseul Park[SUP] 1 [/SUP], Nam-Gun Kim[SUP] 3 [/SUP], Byung-Soo Kim[SUP] 4 [/SUP], Yongdoo Park[SUP] 2 [/SUP], Young Kyung Yoon[SUP] 5 [/SUP], Jongseong Kim[SUP] 1 2 [/SUP]
Affiliations
The efficacy of coronavirus disease 2019 (COVID-19) vaccination is closely related to the serum levels of SARS-CoV-2-neutralizing antibodies (NAb) that bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Therefore, the rapid and quantitative measurement of SARS-CoV-2 NAb in the sera of vaccinated individuals is essential to develop an effective vaccine and further achieve population immunity, that is, herd immunity. The plaque reduction neutralization test, the gold standard for NAb effectiveness in serological tests, is accurate but requires biosafety level 3 facilities because of the use of the virus, which hampers its application in common laboratories and clinical practice. Here, we developed a bioresponsive nanogel-based surface plasmon resonance (nSPR) platform that detects SARS-CoV-2 NAb in clinical samples without complicated pretreatment. We found that multivalent protein binding (MPB) between the nanogel-conjugated RBD protein and SARS-CoV-2 NAb yields significantly enhanced SPR signals compared to the nonspecific interference from serum proteins in the nSPR assay. The excellence of our nanogel-based SARS-CoV-2 NAb test is due to its selectivity for NAb, with resistance to all other proteins, allowing the rapid detection and quantification of NAbs in each individual. Importantly, this nSPR assay provides a NAb detection platform for easier and safer COVID-19 vaccination strategies.
. 2023 Feb 23;acsapm.2c02187.
doi: 10.1021/acsapm.2c02187. Online ahead of print. Method for the Rapid Detection of SARS-CoV-2-Neutralizing Antibodies Using a Nanogel-Based Surface Plasmon Resonance Biosensor
Su-Kyoung Lee[SUP] 1 2 [/SUP], Bora Yim[SUP] 1 2 [/SUP], Jinseul Park[SUP] 1 [/SUP], Nam-Gun Kim[SUP] 3 [/SUP], Byung-Soo Kim[SUP] 4 [/SUP], Yongdoo Park[SUP] 2 [/SUP], Young Kyung Yoon[SUP] 5 [/SUP], Jongseong Kim[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37552750
- PMCID: PMC9969888
- DOI: 10.1021/acsapm.2c02187
The efficacy of coronavirus disease 2019 (COVID-19) vaccination is closely related to the serum levels of SARS-CoV-2-neutralizing antibodies (NAb) that bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Therefore, the rapid and quantitative measurement of SARS-CoV-2 NAb in the sera of vaccinated individuals is essential to develop an effective vaccine and further achieve population immunity, that is, herd immunity. The plaque reduction neutralization test, the gold standard for NAb effectiveness in serological tests, is accurate but requires biosafety level 3 facilities because of the use of the virus, which hampers its application in common laboratories and clinical practice. Here, we developed a bioresponsive nanogel-based surface plasmon resonance (nSPR) platform that detects SARS-CoV-2 NAb in clinical samples without complicated pretreatment. We found that multivalent protein binding (MPB) between the nanogel-conjugated RBD protein and SARS-CoV-2 NAb yields significantly enhanced SPR signals compared to the nonspecific interference from serum proteins in the nSPR assay. The excellence of our nanogel-based SARS-CoV-2 NAb test is due to its selectivity for NAb, with resistance to all other proteins, allowing the rapid detection and quantification of NAbs in each individual. Importantly, this nSPR assay provides a NAb detection platform for easier and safer COVID-19 vaccination strategies.